<DOC>
	<DOC>NCT02805205</DOC>
	<brief_summary>The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.</brief_summary>
	<brief_title>PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Patients with age between 18 and 70 years diagnosis of breast cancer patients who need to receive multicycle chemotherapy grade III/IV neutropenia after chemotherapy KPS scoreâ‰¥70 life expectancy of at least 3 months Written informed consent are acquired Have accepted any other drug related clinical trial within 4 weeks before anticipated uncontrolled infection pregnancy Other situations that investigators consider as contraindication for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>PEG-rhG-CSF neutropenia</keyword>
</DOC>